Biogen Inc. (BIIB)
| Market Cap | 28.56B +63.3% |
| Revenue (ttm) | 9.94B +1.2% |
| Net Income | 1.37B -7.3% |
| EPS | 9.30 -8.1% |
| Shares Out | 147.64M |
| PE Ratio | 20.81 |
| Forward PE | 14.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 879,891 |
| Open | 189.68 |
| Previous Close | 191.38 |
| Day's Range | 189.50 - 195.20 |
| 52-Week Range | 115.25 - 202.41 |
| Beta | 0.19 |
| Analysts | Buy |
| Price Target | 209.19 (+8.14%) |
| Earnings Date | Apr 29, 2026 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price target is $209.19, which is an increase of 8.14% from the latest price.
News
Eisai, Biogen announce FDA extension of review period for lecanemab-irmb sBLA
Eisai (ESAIY) and Biogen (BIIB) announced that the FDA has extended the review period by three months for the supplemental biologics license application, or sBLA, for a once-weekly lecanemab-irmb subc...
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., May 8, 2026 /PRNewswire/ -- Eisai Co., Ltd.
Remitly Global to replace Apellis in S&P 600 at open on 5/14
Remitly Global (RELY) will replace Apellis Pharmaceuticals (APLS). S&P 500 constituent Biogen (BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing condit...
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Famil...
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Biogen upgraded to Buy from Hold at Freedom Broker
Freedom Broker analyst Ilya Zubkov upgraded Biogen (BIIB) to Buy from Hold with a price target of $245, up from $185. The firm views the company’s acquisition of Apellis (APLS)
Biogen price target raised to $190 from $189 at Truist
Truist raised the firm’s price target on Biogen (BIIB) to $190 from $189 and keeps a Hold rating on the shares. The firm has updated its model after the company’s
Biogen price target raised to $200 from $190 at Citi
Citi raised the firm’s price target on Biogen (BIIB) to $200 from $190 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q1
Biogen price target raised to $206 from $200 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Biogen (BIIB) to $206 from $200 and keeps an Equal Weight rating on the shares. The company reported a Q1 revenue and
Biogen price target raised to $222 from $213 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Biogen (BIIB) to $222 from $213 and keeps an Outperform rating on the shares after its Q1 earnings beat.
Biogen price target raised to $196 from $191 at Wedbush
Wedbush raised the firm’s price target on Biogen (BIIB) to $196 from $191 and keeps a Neutral rating on the shares. While the firm anticipated Q1 would likely be a
Biogen price target raised to $260 from $246 at Guggenheim
Guggenheim raised the firm’s price target on Biogen (BIIB) to $260 from $246 and keeps a Buy rating on the shares. Management expressed confidence that with successful execution of the
Biogen price target raised to $203 from $200 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Biogen (BIIB) to $203 from $200 and keeps a Neutral rating on the shares. The firm views the strength in
Biogen Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue rise 2% to $2.5B, with growth products up 12% and surpassing legacy MS. High Dose SPINRAZA and LEQEMBI drove performance, while the Apellis acquisition is set to expand the portfolio and be accretive to EPS in 2027.
Biogen Lowers 2026 Earnings Outlook
Biogen lowered its earnings guidance and projected weaker revenue for 2026, tempering the impact of a first-quarter rise in both sales and profit.
Biogen lowers FY26 adjusted EPS view to $14.25-$15.25, consensus $15.55
Full year 2026 total revenue expected to decline by a mid-single digit percentage versus full year 2025. Full year 2026 Non-GAAP diluted EPS is now expected to be between $14.25
Biogen reports Q1 adjusted EPS $3.57, consensus $2.95
Reports Q1 revenue $2.48B, consensus $2.25B. President and Chief Executive Officer Christopher Viehbacher said: “We significantly advanced our transformation into the New Biogen (BIIB) through strong ...
Biogen cuts annual profit forecast on acquisition-related charges
Biogen cut its full-year profit forecast on Wednesday as it booked acquisition-related charges, although its first-quarter earnings beat expectations on better-than-estimated sales of its Alzheimer's...
Biogen price target raised to $200 from $197 at BofA
BofA raised the firm’s price target on Biogen (BIIB) to $200 from $197 and keeps a Neutral rating on the shares ahead of Q1 results. Biogen’s first quarter should be
Biogen upgraded to Buy from Neutral at UBS
UBS analyst Michael Yee upgraded Biogen (BIIB) to Buy from Neutral with a price target of $225, up from $185. The firm has increased conviction on Biogen’s pipeline catalysts coming
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma
Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater China to an experimental immune disease treatment from Chinese biotech firm TJ Biopharma, giving ...
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive agreem...
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collabora...
Why This Pharma Stock More Than Doubled Today
A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.